aztreonam has been researched along with Candidiasis in 2 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Candidiasis: Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhanasekaran, S | 3 |
| Selvadoss, PP | 3 |
| Manoharan, SS | 3 |
| Zingman, BS | 1 |
2 other studies available for aztreonam and Candidiasis
| Article | Year |
|---|---|
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Anti-Fungal Potential of Structurally Diverse FDA-Approved Therapeutics Targeting Secreted Aspartyl Proteinase (SAP) of Candida albicans: an In Silico Drug Repurposing Approach.
Topics: Anti-Bacterial Agents; Aspartic Acid Endopeptidases; Aspartic Acid Proteases; Aztreonam; Candida alb | 2023 |
Fever after cytotoxic therapy of chronic lymphocytic leukemia.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Aztreonam; Candidiasis; Female; | 1999 |